Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
NCT02453711
Completed
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2020
Locations: Novo Nordisk Investigational Site, Anaheim, California +73 locations
Conditions: Metabolism and Nutrition Disorder, Obesity
Register for Updates
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
NCT02827708
Completed
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2020
Locations: Novo Nordisk Investigational Site, Tuscumbia, Alabama +116 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
NCT03136484
Completed
This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) on a background treatment of metformin
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2020
Locations: Novo Nordisk Investigational Site, Anaheim, California +118 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
NCT02648204
Completed
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2019
Locations: Novo Nordisk Investigational Site, Tuscumbia, Alabama +208 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
NCT03191396
Completed
This study is conducted in Europe. The aim of the study is to compare the effect of semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg once-daily on blood sugar levels after 30 weeks of treatment in people with type 2 diabetes. The study will last approximately 9 months (37 weeks). Each participant will have 7 visits at the clinic and 3 phone calls with the study doctor. At the visits, participants will have a number of tests, for example: general health... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2019
Locations: Novo Nordisk Investigational Site, Burgas, Not set +91 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
NCT00696657
Completed
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment allocation to semaglutide or placebo was double-blind, whereas liraglutide treatment was administered open-label.Primary efficacy parameter was HbA1c and the treatment duration was 12 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2019
Locations: Novo Nordisk Investigational Site, Gratwein, Not set +76 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
NCT02461589
Completed
This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2019
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +149 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
NCT01720446
Completed
This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopp... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/20/2019
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +252 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
NCT02128932
Completed
This trial is conducted in Africa, North and South America, Asia and Europe. The purpose of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus insulin glargine once-daily on glycaemic control after 30 weeks of treatment in insulin-naïve subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2019
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +230 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
NCT02054897
Completed
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2019
Locations: Novo Nordisk Investigational Site, Anniston, Alabama +85 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
NCT01885208
Completed
This trial is conducted in Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of semaglutide once-weekly versus exenatide ER (extended release) 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2019
Locations: Novo Nordisk Investigational Site, Anniston, Alabama +145 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects
NCT03010475
Completed
This trial is conducted in Europe. Tha aim of this trial is to investigate the effect of oral semaglutide on the pharmacokinetics of furosemide and rosuvastatin in healthy subjects.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/19/2017
Locations: Novo Nordisk Investigational Site, Harrow, Not set
Conditions: Diabetes, Healthy
Register for Updates